Dayton Therapeutics

[Dayton Therapeutics @DaytonThx]

New publication shows high cytotoxic activity of lipophilic #satraplatin in genetically defined hematological malignancies, surprisingly distinct from cisplatin.
https://t.co/H0TIIk98w0

[Dayton Therapeutics @DaytonThx]

We are very happy to announce that pharma& has entered into an agreement with Dayton Therapeutics to acquire the global rights for satraplatin.
https://t.co/koFgq1KsUl

[Thilo J. Zander @ThiloZander]

Many will later say "it was so obvious that satraplatin works in primary CNS lymphoma."
InConversation: @felix_dahm combining oncologist intelligence with AI @DaytonThx https://t.co/i89IzA5Ryz

[Dayton Therapeutics @DaytonThx]

Interview with our CEO @felix_dahm by Nick Herbert at @LaingBuisson https://t.co/aAGuNe9Xio

[Thilo J. Zander @ThiloZander]

Reformulated chemo is back!

Onivyde beats Gem/Abraxane in 1st line metastatic pancreatic cancer. Positive phase 3 trials are rare and highly welcome in this disease.

https://t.co/UdniLLwjU3

[Dayton Therapeutics @DaytonThx]

Meet our Japan representative Haruko Minami @SCCIJ https://t.co/HSlKtV5xsW

[Dayton Therapeutics @DaytonThx]

Zug Innovation Day 2022 #InnoDayZug @Tech_Forum_Zug @ThiloZander @felix_dahm

[Dayton Therapeutics @DaytonThx]

Dayton Therapeutics Discovers New Therapeutic Uses of Satraplatin for Treatment of Rare Lymphomas
https://t.co/VpYUUQNl4w
#satraplatin #lymphoma #oncology

[Dayton Therapeutics @DaytonThx]

Find us at the Zug Innovation Day 2022 on September 21 at Theater Casino Zug #ZugerInnoTag @Tech_Forum_Zug

[Dayton Therapeutics @DaytonThx]

Satraplatin is not approved as a drug yet, but given the favourable toxicity profile and molecular targeting of lipophilic satraplatin, a rational clinical development guided by knowledge of tumour biology and optimal patient selection is warranted.

[Dayton Therapeutics @DaytonThx]

New publication shows high cytotoxic activity of lipophilic #satraplatin in genetically defined hematological malignancies, surprisingly distinct from cisplatin.
https://t.co/H0TIIk98w0

[Dayton Therapeutics @DaytonThx]

Satraplatin's clinically well-documented milder toxicity profile (no nephrotoxicity, no neurotoxicity, no hair-loss) and convenience of oral administration make it unique within this class of drugs.

[Dayton Therapeutics @DaytonThx]

Congratulations to @AadiBioscience, on the #FDA approval of nab-sirolimus for the treatment of the rare cancer PEComa

https://t.co/fvCXQKkS1P

[Thilo J. Zander @ThiloZander]

Calculating IMWG #myeloma response is bothersome and complicated. So we programmed an app for education. It was tricky but we did it. Feel free to check it out. Comments are welcome.

https://t.co/QGBxsJnNOP

[E3 Life Capital @E3Lifescience]

Check out our Myeloma Response app #ASH21 #mmsm #myeloma

https://t.co/nMSZw6MZwq

[Dayton Therapeutics @DaytonThx]

Our new website is live! Learn more about Dayton Therapeutics under https://t.co/4HaW0K9EFf

#daytontherapeutics #orphandrugs #oncology

[FierceBiotech @FierceBiotech]

#ASCO21 "85% of [teclistamab] responders are still in remission at seven months, so the median is going to be far north of that, which, for a single agent in this population, is very, very encouraging” https://t.co/ig37zDhJCd

[Dayton Therapeutics @DaytonThx]

FDA advisors will scrutinise three cancer immunotherapies granted conditional approvals at a three-day meeting this week, to see if they should stay on the market.
https://t.co/Xxm2kcaIVN